Cita APA

Hirschberg, A. L., Sánchez-Rovira, P., Presa-Lorite, J., Campos-Delgado, M., Gil-Gil, M., Lidbrink, E., . . . Nieto-Magro, C. (2020). Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: A phase II, randomized, double-blind, placebo-controlled trial. Menopause.

Citación estilo Chicago

Hirschberg, Angelica Lindén, Pedro Sánchez-Rovira, Jesús Presa-Lorite, Miriam Campos-Delgado, Miguel Gil-Gil, Elisabet Lidbrink, Javier Suárez-Almarza, y Concepción Nieto-Magro. "Efficacy and Safety of Ultra-low Dose 0.005% Estriol Vaginal Gel for the Treatment of Vulvovaginal Atrophy in Postmenopausal Women With Early Breast Cancer Treated With Nonsteroidal Aromatase Inhibitors: A Phase II, Randomized, Double-blind, Placebo-controlled Trial." Menopause 2020.

Cita MLA

Hirschberg, Angelica Lindén, et al. "Efficacy and Safety of Ultra-low Dose 0.005% Estriol Vaginal Gel for the Treatment of Vulvovaginal Atrophy in Postmenopausal Women With Early Breast Cancer Treated With Nonsteroidal Aromatase Inhibitors: A Phase II, Randomized, Double-blind, Placebo-controlled Trial." Menopause 2020.